Ims Health News

Buyouts are finally returning for the deal-hungry private equity industry, which is looking at 2010 to deploy huge cash reserves into deals that buyers hope could get back up to double-digit billions.

A 13-year-old boy was probably in hot water with his father after running up a cell phone bill of nearly $22,000. Ted Estarija says he was expecting his bill to be higher this month after adding his son to his plan, but wasn't expecting a bill of $21,917 in data usage charges.

Shares of IMS Health Inc. tumbled Friday, a day after an amendment was introduced to the Senate health care overhaul bill that would effectively ban pharmaceutical data mining.

IMS Health Incorporated , the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced that it has established a record date and a meeting date for a special meeting of its stockholders to consider and vote upon a proposal to adopt the previously announced merger agreement, dated as of ...

November retail sales increased 1.3% from the revised October sales of 1.1%. November import price index increased 1.7% driven by a surge of 7.3% in fuel prices.

The trader may be unraveling a portion of a bearish risk reversal established back in late-September. It appears 62,500 puts were sold at the March 10 strike for 53 cents apiece, spread against the purchase of the same number of calls at the January 2011 12 strike for 24 cents premium each.

The following stocks were among those that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market: NYSE: Alcoa Inc., up $1.11 to $14.61 A JPMorgan analyst boosted his profit estimates on the aluminum maker because he expects metal prices will rise next year.

Shares of drug information provider IMS Health Inc. fell on Friday on concerns a Senate health care bill proposal may block drug companies' access to prescription information.

Drug companies would no longer be able to mine pharmacy records to track which doctors are prescribing their medications, under a proposal unveiled Thursday by two Senate Democrats.

Pfizer Inc ., which became the biggest drugmaker selling widely prescribed pills such as the Lipitor heart medicine, is preparing to enter the business of making cheaper copies of pricey, injectable drugs from biotechnology.

IndexIQ recently introduced the IQ ARB Merger Arbitrage ETF intended to track the IQ ARB Merger Arbitrage Index.

The pharmaceutical industry may have to cough up more than the $80 billion it agreed to contribute to President Barack Obama's health overhaul effort, reflecting pressure from Democrats and their supporters for more money to cover older and low-income people.

Alternative Investment Capital Ltd. , majority owned by Mitsubishi Corp. , plans to start a new fund to invest in Asian private equity next year, as the industry emerges from a two-year slump triggered by a credit freeze.

King Pharmaceuticals Inc., LifePoint Hospitals Inc. and Endo Pharmaceuticals Holdings Inc.

Canada pension funds and private equity are eyeing income trusts with steady earnings and resource companies as homes for cash held over during the economic crisis as acquisitions bubble up again after a recession-induced deep freeze.

Albert Einstein Healthcare Network , Philadelphia, has appointed Richard C. Sheerr chairman of the board of trustees, the governing body of the organization, and the board of overseers, which acts in an advisory and fund-raising capacity.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/11/09, AVANIR Pharmaceuticals, Inc.

A drug company is expanding its operations in North Carolina, adding nearly 260 jobs.

Progressives may have a stronger hand than they thought: Stupak amendment only brought in 6-10 votes -- Reid's speed round: Sections of bill hashed out privately to try to meet Christmas deadline Main Content Progressives may have a stronger hand than they thought: Stupak amendment only brought in 6-10 votes -- Reid's speed round: Sections of bill ...

IMS Health , the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the upcoming launch of IMS Oncology Quantifier TM , a comprehensive, clinically rich analytical tool that enables the company's clients to assess treatment opportunities and guide commercial decisions in the $48 billion ...